



Biolight Life Sciences Ltd. ("the Company")

September 8, 2025

To: Israel Securities Authority www.isa.gov.il

To: Tel-Aviv Stock Exchange Ltd. www.tase.co.il

Re: Initial Review of a Potential Public Equity Offering

The Company is pleased to announce that it is in the preliminary stages of considering a public equity offering. This offering may include a public offer of the Company's ordinary shares and warrants convertible into the Company's ordinary shares, to be issued through a shelf offering report under the Company's shelf prospectus.

Please note that this is only a preliminary review. The Company is not committed to carrying out such an equity offering, and there is no certainty regarding the feasibility, timing, size, and/or terms of any such offering. Furthermore, this report does not constitute a public offer or an invitation to purchase the Company's securities, and no securities should be purchased based on this report.

Any offering of securities by the Company to the public, if and when it takes place, will be made through the publication of a shelf offering report in accordance with the Company's shelf prospectus. This is subject to obtaining all necessary legal approvals, including approval from the Company's authorized organs and approval from the Tel Aviv Stock Exchange Ltd. to publish the shelf offering report and list the issued securities for trading.

Sincerely,

Biolight Life Sciences Ltd.

NON-BINDING TRANSLATION

The above-mentioned immediate report is a free translation of the Company's immediate report in Hebrew published on the TASE on September 8, 2025. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.